UBS Group
NDRM

UBS Group’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

UBS Group’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-96,452
Closed -$3.75M – 8516
2017
Q3 		$3.75M Buy
96,452
+94,102
+4,004% +$3.46M ﹤0.01% 2503
2017
Q2 		$70K Buy
2,350
+1,659
+240% +$43K ﹤0.01% 5426
2017
Q1 		$18K Sell
691
-1,154
-63% -$28.6K ﹤0.01% 6248
2016
Q4 		$41K Buy
1,845
+340
+23% +$6.36K ﹤0.01% 5990
2016
Q3 		$28K Buy
1,505
+99
+7% +$1.72K ﹤0.01% 6025
2016
Q2 		$23K Buy
1,406
+863
+159% +$14.5K ﹤0.01% 6204
2016
Q1 		$8K Sell
543
-1,017
-65% -$13.7K ﹤0.01% 6824
2015
Q4 		$27K Sell
1,560
-50
-3% -$974 ﹤0.01% 6451
2015
Q3 		$33K Buy
1,610
+307
+24% +$6.3K ﹤0.01% 6222
2015
Q2 		$20K Buy
1,303
+251
+24% +$3.53K ﹤0.01% 6896
2015
Q1 		$14K Buy
1,052
+327
+45% +$4.02K ﹤0.01% 7407
2014
Q4 		$10K Buy
+725
New +$5.73K ﹤0.01% 8454

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

UBS Group's NDRM Position: Q4 2017 in Review

UBS Group sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 96,452 shares — an estimated $3.75M sold.

UBS Group first reported a position in NDRM in Q4 2014 and held it in 12 quarters. The position peaked at $3.75M in Q3 2017. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • UBS Group reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • UBS Group sold 96,452 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $3.75M.
  • UBS Group first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2014 and held it in 12 quarters.
  • UBS Group's NeuroDerm Ltd. Ordinary Shares position peaked at $3.75M in Q3 2017.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on UBS Group's 13F filing for Q4 2017, filed 14 Feb 2018.